Andor W. J. M. Glaudemans

ORCID: 0000-0001-8081-0641
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Medical Imaging Techniques and Applications
  • Radiopharmaceutical Chemistry and Applications
  • Orthopedic Infections and Treatments
  • Infectious Diseases and Tuberculosis
  • Radiomics and Machine Learning in Medical Imaging
  • Hematological disorders and diagnostics
  • Infective Endocarditis Diagnosis and Management
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Medical Imaging and Pathology Studies
  • Sarcoidosis and Beryllium Toxicity Research
  • Estrogen and related hormone effects
  • Parathyroid Disorders and Treatments
  • Cardiac Imaging and Diagnostics
  • HER2/EGFR in Cancer Research
  • Vasculitis and related conditions
  • Lymphoma Diagnosis and Treatment
  • Advanced X-ray and CT Imaging
  • Breast Cancer Treatment Studies
  • Brain Metastases and Treatment
  • Prostate Cancer Treatment and Research
  • Cancer Immunotherapy and Biomarkers
  • Streptococcal Infections and Treatments
  • Neuroendocrine Tumor Research Advances
  • Advanced MRI Techniques and Applications
  • Infectious Aortic and Vascular Conditions

University of Groningen
2016-2025

University Medical Center Groningen
2016-2025

University of Twente
2022-2024

European Association of Nuclear Medicine
2021-2024

Imaging Center
2018-2021

Weatherford College
2021

Dialyse Centrum Groningen
2012-2021

Society of Nuclear Medicine and Molecular Imaging
2014-2021

Fundación Juan March
2020

Oxford University Press (United Kingdom)
2020

Background— Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal cardiomyopathy for which several promising therapies are in development. The diagnosis frequently delayed or missed because of the limited specificity echocardiography traditional requirement histological confirmation. It has long been recognized that technetium-labeled bone scintigraphy tracers can localize to myocardial amyloid deposits, use this imaging modality cardiac ATTR lately revisited. We conducted...

10.1161/circulationaha.116.021612 article EN Circulation 2016-04-23

Abstract It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, sufficient for maximal ER downregulation in patients with metastatic breast cancer. We performed a feasibility study to assess availability before and during fulvestrant. Sixteen ER-positive cancer underwent positron emission tomography/computed tomography (PET/CT) at baseline (scan 1), day 28 2), 84 3) monitor tumor [18F]fluoroestradiol (FES) uptake. Incomplete reduction was predefined as...

10.1158/2159-8290.cd-14-0697 article EN Cancer Discovery 2014-11-08

For the diagnosis of prosthetic joint infection, real evidence-based guidelines to aid clinicians in choosing most accurate diagnostic strategy are lacking. To address this need, we performed a multidisciplinary systematic review relevant nuclear medicine, radiological, orthopaedic, infectious, and microbiological literature define accuracy each technique provide answers on uniform statements for topic that was found be important develop commonly agreed upon flowchart. The approach used...

10.1007/s00259-019-4263-9 article EN cc-by European Journal of Nuclear Medicine and Molecular Imaging 2019-01-26

18F-Fluorodeoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) was recently introduced as a new tool for the diagnosis of prosthetic heart valve endocarditis (PVE). Previous studies reporting modest diagnostic accuracy may have been hampered by unstandardized image acquisition and assessment, several confounders, well. The aim this study to improve performance FDG PET/CT in patients whom PVE suspected identifying excluding possible using both visual standardized...

10.1161/circulationaha.118.035032 article EN Circulation 2018-07-17

Abstract Purpose The goal of this guideline/procedure standard is to assist nuclear medicine physicians, other professionals, oncologists or medical specialists for recommended use [ 18 F]FDG PET/CT in oncological patients undergoing immunotherapy, with special focus on response assessment solid tumors. Methods In a cooperative effort between the EANM, SNMMI and ANZSNM, clinical indications, imaging procedures reporting standards have been agreed upon summarized joint standard. Conclusions...

10.1007/s00259-022-05780-2 article EN cc-by European Journal of Nuclear Medicine and Molecular Imaging 2022-04-04

16α-(18)F-fluoro-17β-estradiol ((18)F-FES) is an estrogen receptor (ER)-specific PET tracer with various potential interesting applications. The precise contribution of this technique in current clinical practice, however, has yet to be determined. Therefore, the aim study was evaluate value (18)F-FES breast cancer patients presenting a dilemma.(18)F-FES examination could requested by referring physicians for history ER-positive and presence dilemma despite complete standard work-up. All...

10.2967/jnumed.111.092734 article EN Journal of Nuclear Medicine 2012-01-12

To assess the usefulness of bone scintigraphy with (99m)Technetium-hydroxymethylene diphosphonate ((99m)Tc-HDP) for detection cardiac involvement in a group patients ATTR amyloidosis different phases disease, to relate findings echocardiography, ECG and biomarkers, evaluate scintigraphic techniques calculation methods quantification uptake correlation echocardiographic features biomarkers.Forty-one underwent clinical examinations, ECG, measurement biomarkers (planar imaging SPECT-CT) were...

10.3109/13506129.2013.871250 article EN Amyloid 2014-01-23

Giant cell arteritis (GCA) is the most frequent form of vasculitis in persons older than 50 years. Cranial and systemic large vessels can be involved. [¹⁸F] fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed (CT) increasingly used to diagnose inflammation arteries GCA. Unfortunately, no consensus exists on preferred scoring method. In present study, we aim define optimal FDG PET/CT method for GCA diagnosis using temporal artery biopsy clinical as reference scans patients...

10.1097/md.0000000000001542 article EN cc-by-nc Medicine 2015-09-01
Coming Soon ...